Department of Medicine, MacKay Medical College, New Taipei, Taiwan.
Institute of Biomedical Sciences, MacKay Medical College, New Taipei, Taiwan.
J Cell Mol Med. 2024 Jun;28(12):e18489. doi: 10.1111/jcmm.18489.
This study explores the impact of senescence on autocrine C-C motif chemokine ligand 5 (CCL5) in human endothelial progenitor cell (EPCs), addressing the poorly understood decline in number and function of EPCs during ageing. We examined the effects of replication-induced senescence on CCL5/CCL5 receptor (CCR5) signalling and angiogenic activity of EPCs in vitro and in vivo. We also explored microRNAs controlling CCL5 secretion in senescent EPCs, its impact on EPC angiogenic activity, and validated our findings in humans. CCL5 secretion and CCR5 levels in senescent EPCs were reduced, leading to attenuated angiogenic activity. CCL5 enhanced EPC proliferation via the CCR5/AKT/P70S6K axis and increased vascular endothelial growth factor (VEGF) secretion. Up-regulation of miR-409 in senescent EPCs resulted in decreased CCL5 secretion, inhibiting the angiogenic activity, though these negative effects were counteracted by the addition of CCL5 and VEGF. In a mouse hind limb ischemia model, CCL5 improved the angiogenic activity of senescent EPCs. Analysis involving 62 healthy donors revealed a negative association between CCL5 levels, age and Framingham Risk Score. These findings propose CCL5 as a potential biomarker for detection of EPC senescence and cardiovascular risk assessment, suggesting its therapeutic potential for age-related cardiovascular disorders.
本研究探讨了衰老对人内皮祖细胞(EPC)自分泌 C-C 基序趋化因子配体 5(CCL5)的影响,旨在阐明衰老过程中 EPC 数量和功能下降的原因。我们研究了复制诱导的衰老对 EPC 中 CCL5/CCL5 受体(CCR5)信号转导和血管生成活性的影响,分别在体外和体内进行了检测。我们还研究了控制衰老 EPC 中 CCL5 分泌的 microRNA,其对 EPC 血管生成活性的影响,并在人类中验证了我们的发现。衰老 EPC 中的 CCL5 分泌和 CCR5 水平降低,导致血管生成活性减弱。CCL5 通过 CCR5/AKT/P70S6K 轴促进 EPC 增殖,并增加血管内皮生长因子(VEGF)的分泌。衰老 EPC 中 miR-409 的上调导致 CCL5 分泌减少,抑制血管生成活性,但通过添加 CCL5 和 VEGF 可以抵消这些负效应。在小鼠后肢缺血模型中,CCL5 改善了衰老 EPC 的血管生成活性。对 62 名健康供体的分析显示,CCL5 水平与年龄和 Framingham 风险评分呈负相关。这些发现表明 CCL5 可作为检测 EPC 衰老和心血管风险评估的潜在生物标志物,提示其在与年龄相关的心血管疾病中的治疗潜力。